Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
The DBV Technologies S.A. (DBVT) news page on Stock Titan aggregates company announcements, regulatory disclosures, and clinical development updates for this clinical-stage biopharmaceutical issuer. DBV Technologies focuses on food allergies and other immunologic conditions with significant unmet medical need, using its proprietary Viaskin patch technology and epicutaneous immunotherapy (EPIT) platform.
Investors and followers of DBV Technologies can use this news feed to review company-issued press releases and market announcements. Recent communications from DBV Technologies have covered topics such as progress in its Viaskin Peanut clinical program in peanut-allergic toddlers and children, including the Phase 3 VITESSE trial in children aged 4 to 7 years. The company has reported that VITESSE met its primary endpoint and that safety results were consistent with the existing Viaskin Peanut clinical program, positioning this trial as a key milestone in its development strategy.
In addition to clinical data updates, DBV Technologies news items include information on supplemental safety studies in toddlers, participation in healthcare and investor conferences, and changes in leadership and board composition. The company also releases regulated information related to its Euronext Paris listing, such as monthly disclosures of total shares and voting rights and reports on its liquidity contract.
Regulatory filings summarized in press releases, including U.S. SEC Form 8-K reports, provide insight into financial results, equity financing arrangements, and other corporate events. By following DBV Technologies news, readers can track developments in the Viaskin platform, food allergy programs, and the company’s dual listing on Euronext Paris and the Nasdaq Capital Market.
DBV Technologies announced that CEO Daniel Tassé will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18 at 8:40 am ET. This event will be hosted in a virtual format, allowing interested parties to access the webcast through the Investors & Media section of the Company’s website. A replay will be available after the event.
DBV Technologies, based in Montrouge, France, focuses on developing Viaskin™, a proprietary technology for food allergy treatment. The Company's shares trade under the ticker DBVT on Nasdaq.
DBVT released its monthly report on voting rights and share count as of January 31, 2022. The total number of shares stood at 55,095,762, with the total gross of voting rights also at 55,095,762. The net voting rights, after accounting for shares without voting rights, totaled 54,925,155. This information ensures transparency for investors and complies with regulations set by the Autorité des Marchés Financiers.
DBV Technologies has published its Half-Year Report on the liquidity contract with ODDO BHF as of December 31, 2021.
The liquidity account contained 153,631 shares worth €175,542.33, compared to 24,313 shares and €682,454.94 at the contract's inception in July 2018. In 2021's second half, 1,206 shares were purchased and 1,065 sold, totaling 455,657 shares bought for €3,256,011.54 and 379,901 sold for €2,951,075.39. DBV is advancing Viaskin™, a non-invasive immunotherapy platform targeting food allergies.
DBVT announced its monthly update on voting rights and total shares as of December 31, 2021. The total number of shares outstanding is 55,095,762, while the total gross of voting rights stands at 55,095,762. After accounting for shares without voting rights, the total net voting rights reach 54,942,131. This information complies with the regulations of the Autorité des Marchés Financiers.
DBV Technologies announced that CEO Daniel Tassé will participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference. The event will be available for on-demand viewing starting January 10, 2022, at 7:00 AM ET. Investors can access the webcast on the company's website, where a replay will also be available post-event. DBV Technologies is focused on developing Viaskin™, an innovative immunotherapy platform aimed at treating food allergies, with ongoing clinical trials for Viaskin Peanut.
DBV Technologies announced plans to begin a pivotal Phase 3 study for its modified Viaskin Peanut patch aimed at children. This follows FDA feedback suggesting a sequential development approach, which DBV deemed inefficient. Instead, the company will conduct a Phase 3 placebo-controlled trial to demonstrate the patch's safety and effectiveness. In parallel, DBV has withdrawn its Marketing Authorization Application for Viaskin Peanut from the EMA due to insufficient data from a single pivotal study. The company believes that new data will better support its application for regulatory approval.
DBVT reported its monthly update on voting rights and share count as of November 30, 2021. The total number of shares stands at 55,090,362, indicating a consistent share base. The total number of voting rights is 55,090,362 gross and 54,983,362 net, after accounting for shares without voting rights. This information complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers, ensuring transparency for investors and stakeholders.
DBV Technologies, a clinical-stage biopharmaceutical company, announced participation in the 4th Annual Evercore ISI HealthCONx Conference on December 1, 2021. CEO Daniel Tassé will engage in a fireside chat at 8am ET. A live webcast will be available on the company’s website, with a replay following the event. DBV Technologies is focused on developing Viaskin, a proprietary platform aimed at food allergy treatment through epicutaneous immunotherapy. The company's shares are traded on Euronext and Nasdaq under symbols DBV and DBVT, respectively.
DBVT has released information on the total number of voting rights and shares as of October 31, 2021. The company has a total of 55,011,687 shares, with 54,910,187 voting rights net of non-voting shares. This report complies with Article 223-16 of the General Regulations set by Autorité des Marchés Financiers. The data is crucial for shareholders and potential investors as it reflects the company's governance structure and shareholder engagement.
DBV Technologies announced it will present new long-term data from the REALISE trial at the ACAAI 2021 Annual Scientific Meeting, Nov. 4-8, 2021. The study focuses on the safety and health-related quality of life impacts of its lead product, Viaskin™ Peanut (DBV712), in children aged 4-11. An oral presentation and a poster presentation will showcase key findings from three years of data. The company aims to demonstrate the potential real-world applications of Viaskin Peanut, which targets peanut allergy treatment through a novel epicutaneous patch technology.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
